Advances in 177Lu-PSMA and 225Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer

被引：36
|
作者：
Ling, Sui Wai [1 ]
de Blois, Erik [1 ]
Hooijman, Eline [1 ,2 ]
van der Veldt, Astrid [1 ,3 ]
Brabander, Tessa [1 ]
机构：
[1] Erasmus MC, Dept Radiol & Nucl Med, NL-3015 GD Rotterdam, Netherlands
[2] Erasmus MC, Dept Hosp Pharm, NL-3015 GD Rotterdam, Netherlands
[3] Erasmus MC Canc Inst, Dept Med Oncol, NL-3015 GD Rotterdam, Netherlands
来源：
PHARMACEUTICS | 2022年 / 14卷 / 10期
关键词：
actinium-225; lutetium-177; prostate-specific membrane antigen (PSMA); metastatic castration-resistant prostate cancer (mCRPC); radionuclide therapy (RNT); TARGETED ALPHA-THERAPY; MEMBRANE ANTIGEN-EXPRESSION; RADIOLIGAND THERAPY; DOSIMETRY ESTIMATE; PSMA; ADENOCARCINOMA; ACTINIUM-225; EFFICACY;
D O I：
10.3390/pharmaceutics14102166
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
For patients with metastatic castration-resistant prostate cancer (mCRPC), the survival benefit of classic treatment options with chemotherapy and drugs targeting androgen signaling is limited. Therefore, beta and alpha radionuclide therapy (RNT) have emerged as novel treatment options for patients with mCRPC. Radioligands target the prostate-specific membrane antigen (PSMA) epitopes, which are upregulated up to a thousand times more in prostate cancer cells compared to the cells in normal tissues. For this reason, PSMA is an excellent target for both imaging and therapy. Over the past years, many studies have investigated the treatment effects of lutetium-177 labeled PSMA (Lu-177-PSMA) and actinium-225 labeled PSMA (Ac-225-PSMA) RNT in patients with mCRPC. While promising results have been achieved, this field is still in development. In this review, we have summarized and discussed the clinical data of Lu-177-PSMA and Ac-225-PSMA RNT in patients with mCRPC.
引用
收藏
页数：17
相关论文
共 50 条
  • [31] Radionuclide therapy with 177Lu PSMA for prostate cancer
    da Rocha, Euclides Timoteo
    BIOPHYSICAL REVIEWS, 2021, 13 (06) : 1527 - 1527
  • [32] Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding
    Kratochwil, Clemens
    Bruchertseifer, Frank
    Rathke, Hendrik
    Bronzel, Marcus
    Apostolidis, Christos
    Weichert, Wilko
    Haberkorn, Uwe
    Giesel, Frederik L.
    Morgenstern, Alfred
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (10) : 1624 - 1631
  • [33] 177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer
    Fendler, Wolfgang P.
    Kratochwil, Clemens
    Ahmadzadehfar, Hojjat
    Rahbar, Kambiz
    Baum, Richard P.
    Schmidt, Matthias
    Pfestroff, Andreas
    Luetzen, Ulf
    Prasad, Vikas
    Heinzel, Alexander
    Heuschkel, Martin
    Ruf, Juri
    Bartenstein, Peter
    Krause, Bernd J.
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2016, 55 (03): : 123 - 128
  • [34] Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen)
    Belli, Maria Luisa
    Sarnelli, Anna
    Mezzenga, Emilio
    Cesarini, Francesco
    Caroli, Paola
    Di Iorio, Valentina
    Strigari, Lidia
    Cremonesi, Marta
    Romeo, Antonino
    Nicolini, Silvia
    Matteucci, Federica
    Severi, Stefano
    Paganelli, Giovanni
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [35] Overview of selected completed prospective studies on PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer
    Karimzadeh, Amir
    Lehnert, Wencke
    Koehler, Daniel
    Shenas, Farzad
    Kisters, Anna
    Apostolova, Ivayla
    Klutmann, Susanne
    Adam, Gerhard
    Sauer, Markus
    ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN, 2025,
  • [36] PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under 177Lu-PSMA-617 Radioligand Therapy
    Widjaja, Liam
    Werner, Rudolf A.
    Ross, Tobias L.
    Bengel, Frank M.
    Derlin, Thorsten
    CANCERS, 2021, 13 (12)
  • [37] Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Bal, Chandrashekhar
    Sahoo, Ranjit Kumar
    Damle, Nishikant Avinash
    Tripathi, Madhavi
    Seth, Amlesh
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (01) : 19 - 31
  • [38] Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
    Daniel Groener
    Cam Tu Nguyen
    Justus Baumgarten
    Benjamin Bockisch
    Karen Davis
    Christian Happel
    Nicolai Mader
    Christina Nguyen Ngoc
    Jennifer Wichert
    Severine Banek
    Philipp Mandel
    Felix K. H. Chun
    Nikolaos Tselis
    Frank Grünwald
    Amir Sabet
    EJNMMI Research, 11
  • [39] Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
    Groener, Daniel
    Cam Tu Nguyen
    Baumgarten, Justus
    Bockisch, Benjamin
    Davis, Karen
    Happel, Christian
    Mader, Nicolai
    Ngoc, Christina Nguyen
    Wichert, Jennifer
    Banek, Severine
    Mandel, Philipp
    Chun, Felix K. H.
    Tselis, Nikolaos
    Gruenwald, Frank
    Sabet, Amir
    EJNMMI RESEARCH, 2021, 11 (01)
  • [40] First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Zang, Jie
    Fan, Xinrong
    Wang, Hao
    Liu, Qingxing
    Wang, Jingnan
    Li, Hui
    Li, Fang
    Jacobson, Orit
    Niu, Gang
    Zhu, Zhaohui
    Chen, Xiaoyuan
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (01) : 148 - 158
12345